PANACEA LIFE SCIENCES HOLDINGS Business Summary

Panacea Life Sciences Holdings, Inc. (PLSH) is a vertically integrated holding company specializing in the research, cGMP-certified manufacturing, and multi-channel distribution of plant-based health and wellness products for humans and animals. The company generates revenue through a diversified model encompassing wholesale and direct-to-consumer sales of its PANA-branded lines (cannabinoids, functional mushrooms, kratom, and kava), retail and franchise operations under the "Pana Kava Java" banner, and the "Benivita PLSH" subscription platform, which provides telemedicine and virtual health benefits. Operating a 51,000-square-foot facility in Golden, Colorado, PLSH leverages a strategic partnership with the Colorado State University Cannabinoid Research Center to validate product efficacy through clinical studies. Its primary competitors include Charlotte's Web Holdings, PRF Technologies, Universe Pharmaceuticals, and Clearmind Medicine; PLSH distinguishes itself by controlling the entire value chain from extraction to retail, targeting the premium, science-backed segment of the $134 billion natural wellness market. The company is led by Founder Leslie A. Buttorff, who serves as Chairman, CEO, and CFO, bringing a pedigree in statistics and enterprise management from her previous roles as a Partner at SAP and CEO of Quintel Management Consulting. The executive team includes Jordan Buttorff as Chief Information Officer, responsible for the company’s proprietary ERP and seed-to-sale tracking infrastructure, and Nathan Joel Berman as Secretary and Principal Accounting Officer. The Board of Directors features Larry Wert, a prominent media executive and former President of Broadcast Media for Tribune Media Company, who provides strategic oversight for the company’s retail and brand expansion. PLSH has historically secured institutional support from investors such as Lincoln Park Capital Fund, LLC, and 22nd Century Group, Inc., reinforcing its capital position for strategic acquisitions and clinical research initiatives.